The University of Chicago Header Logo

Connection

Douglas Merkel to Receptor, ErbB-3

Back to Details
This is a "connection" page, showing publications Douglas Merkel has written about Receptor, ErbB-3.
Douglas Merkel
Connection Strength
0.058
Receptor, ErbB-3
  1. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004 Mar 15; 22(6):1071-7.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.